How Wegovy and Compounded Tirzepatide work — mechanism comparison
Wegovy (semaglutide) and Compounded Tirzepatide (tirzepatide (compounded)) belong to overlapping but distinct drug classes. Both work via the incretin (gut-hormone) pathway, but they have different molecular targets:
- Wegovy (semaglutide) — GLP-1 receptor agonist
- Compounded Tirzepatide (tirzepatide (compounded)) — GLP-1 receptor agonist
This mechanistic difference matters because it determines: efficacy (how much weight loss / blood-sugar control you can expect), side-effect profile, dosing schedule, and which patients may benefit most. Read more in our Wegovy mechanism guide and Compounded Tirzepatide mechanism guide.
Efficacy head-to-head
In their respective pivotal trials, mean body-weight reduction reached:
- Wegovy: 14.9% at 68 weeks (trial: STEP-1)
- Compounded Tirzepatide: 22.5% at 72 weeks (trial: SURMOUNT-1)
Compounded Tirzepatide produced 7.6 percentage points more weight loss than Wegovyin head-to-head comparison. Note that trials weren't conducted head-to-head — these are separate trial endpoints in different populations. Real-world differences may be smaller. Individual variability is also large.
Side-by-side radar: Wegovy vs Compounded Tirzepatide
Editorial scoring across 5 dimensions, overlaid. Higher area = better overall fit.
| Axis | Wegovy | Compounded Tirzepatide |
|---|---|---|
| Efficacy | 8 | 10 |
| Convenience | 9 | 9 |
| Affordability | 6 | 5 |
| Tolerance | 5 | 6 |
| Evidence | 10 | 6 |
Higher score = better on that axis. Editorial scoring; not a substitute for prescriber judgment.
Side effects compared
Both drugs share the GLP-1 class side-effect profile — primarily gastrointestinal (nausea, diarrhea, constipation, vomiting) in early treatment, fading as the body adapts. Both carry the FDA boxed warning for thyroid C-cell tumors and contraindications for personal/family history of medullary thyroid carcinoma.
Comparative trial data on common side effects (rates may differ from real-world):
- Nausea rate (Wegovy): 44%
- Nausea rate (Compounded Tirzepatide): 31%
- Diarrhea rate (Wegovy): 30%
- Diarrhea rate (Compounded Tirzepatide): 22%
Patients who tolerate one GLP-1 well often (but not always) tolerate another. Switching between class members typically requires re-titration regardless of prior tolerability. See full side-effect breakdowns for Wegovy and Compounded Tirzepatide.
Dosing schedule comparison
Both medications use step-up titration to minimize side effects, but the schedule details differ:
Wegovy
- Week 1–4: 0.25 mg
- Week 5–8: 0.5 mg
- Week 9–12: 1.0 mg
- Week 13+: 1.7–2.4 mg
Compounded Tirzepatide
- Week 1–4: 2.5 mg
- Week 5–8: 5 mg
- Week 9+: 7.5–15 mg
- Maintenance: Up to 15 mg
See full titration guides for Wegovy dosing and Compounded Tirzepatide dosing.
Cost comparison
Cost differences between Wegovy and Compounded Tirzepatide depend on insurance coverage, manufacturer savings programs, and partner-network pricing — not just retail price.
- Average retail price (Wegovy): $1349/month
- Average retail price (Compounded Tirzepatide): $299/month
- Wegovy savings card: as low as $0/month for eligible commercial-insured
- Compounded Tirzepatide savings card: as low as $0/month for eligible commercial-insured
For most patients, the actual out-of-pocket cost is driven by: (1) what your insurance formulary tier places Wegovy vs Compounded Tirzepatide, (2) whether you qualify for manufacturer savings cards (commercial insurance only), and (3) telehealth partner network availability. Full cost breakdowns: Wegovy cost guide · Compounded Tirzepatide cost guide.
Which one to choose — decision factors
There's no single «better» drug — the right choice depends on individual circumstances. The key decision factors:
Choose Wegovy if…
- Your insurance covers it but not Compounded Tirzepatide
- Your prescriber has more experience with it
- You prefer drugs with longer post-market track record
Choose Compounded Tirzepatide if…
- Your insurance covers it but not Wegovy
- Your prescriber has more experience with it
- Maximum weight loss is your priority (higher mean efficacy)
Switching from Wegovy to Compounded Tirzepatide (or vice versa)
Switching between Wegovy and Compounded Tirzepatide (different active ingredients) typically requires restarting titration from the lowest doseof the new drug. Different molecules have different potencies — your tolerated dose of one doesn't map directly to the other. Plan for:
- Return of titration-period side effects (nausea, GI) for 2-4 weeks on restart
- Possibly temporary weight regain during the transition
- Fresh insurance prior-authorization (different drug = new PA)
- 2-4 weeks for the new drug to reach steady-state plasma levels
FAQ — Wegovy vs Compounded Tirzepatide
Are Wegovy and Compounded Tirzepatide the same drug?
No — they contain different active ingredients (semaglutide and tirzepatide (compounded)). They belong to similar drug classes (GLP-1 family) but work via slightly different molecular targets.
Which is more effective for weight loss?
In separate pivotal trials, Compounded Tirzepatide produced 7.6 percentage points more weight loss than Wegovy on average. However, these were separate trials with different populations — not head-to-head comparison. Individual response variability is also large. Most patients achieve clinically meaningful weight loss with either drug.
Can I take Wegovy and Compounded Tirzepatide together?
No. Combining two GLP-1 receptor agonists provides no added benefit and dramatically increases side-effect risk. Standard practice is to switch between them, not combine.
Which has fewer side effects?
Side-effect profiles are broadly similar across GLP-1 medications — primarily GI effects that fade with adaptation. Individual tolerance varies. Trial data shows comparable rates of nausea, diarrhea, and other common effects between Wegovy and Compounded Tirzepatide.
Will my insurance cover one but not the other?
Often yes. Insurance formularies are negotiated separately per drug — Wegovy may be on Tier 2 of your plan while Compounded Tirzepatide is Tier 4 (or excluded). Check your formulary before assuming both are equally accessible.
Editorial comparison based on FDA prescribing information and published clinical data. Not a substitute for prescriber consultation. Full medical disclaimer.